TY - JOUR
T1 - Dendritic cell immunotherapy in uterine cancer
AU - Coosemans, An
AU - Tuyaerts, Sandra
AU - Vanderstraeten, Anke
AU - Vergote, Ignace
AU - Amant, Frédéric
AU - van Gool, Stefaan W.
PY - 2014
Y1 - 2014
N2 - Uterine cancer is the most common pelvic gynecological malignancy. Uterine sarcomas and relapsed uterine carcinomas have limited treatment options. The search for new therapies is urgent. Dendritic cell (DC) immunotherapy holds much promise, though has been poorly explored in uterine cancer. This commentary gives an insight in existing DC immunotherapy studies in uterine cancer and summarizes the possibilities and the importance of the loading of tumor antigens onto DC and their subsequent maturation. However, the sole application of DC immunotherapy to target uterine cancer will be insufficient because of tumor-induced immunosuppression, which will hamper the establishment of an effective anti-tumor immune response. The authors give an overview on the limited existing immunosuppressive data and propose a novel approach on DC immunotherapy in uterine cancer
AB - Uterine cancer is the most common pelvic gynecological malignancy. Uterine sarcomas and relapsed uterine carcinomas have limited treatment options. The search for new therapies is urgent. Dendritic cell (DC) immunotherapy holds much promise, though has been poorly explored in uterine cancer. This commentary gives an insight in existing DC immunotherapy studies in uterine cancer and summarizes the possibilities and the importance of the loading of tumor antigens onto DC and their subsequent maturation. However, the sole application of DC immunotherapy to target uterine cancer will be insufficient because of tumor-induced immunosuppression, which will hamper the establishment of an effective anti-tumor immune response. The authors give an overview on the limited existing immunosuppressive data and propose a novel approach on DC immunotherapy in uterine cancer
U2 - https://doi.org/10.4161/hv.28716
DO - https://doi.org/10.4161/hv.28716
M3 - Editorial
C2 - 25424788
SN - 2164-5515
VL - 10
SP - 1822
EP - 1827
JO - Human vaccines & immunotherapeutics
JF - Human vaccines & immunotherapeutics
IS - 7
ER -